Completed

Zidovudine, Dideoxyinosine or Dideoxycytidine Combination for HIV Treatment

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Zidovudine

+ Zalcitabine

+ Didanosine

Drug
Who is being recruted

Blood-Borne Infections+13

+ Urogenital Diseases

+ Genital Diseases

Over 13 Years
+42 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorGlaxo Wellcome
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study focuses on human immunodeficiency virus (HIV) disease. It aims to understand the effect of combining two antiviral medications, zidovudine and either 2',3'-Dideoxyinosine (ddI) or 2',3'-Dideoxycytidine (ddC), in managing HIV. The study targets patients living with HIV. Its importance lies in potentially improving the current treatment approach for HIV, which could lead to better care and quality of life for those affected by the virus. During the study, participants receive both zidovudine and either ddI or ddC. The study measures how well these medications work together in reducing the virus in the body. It also assesses their impact on the immune system and evaluates their combined clinical effectiveness. Additionally, the safety and tolerance of using these two medications together are evaluated. The study monitors for any potential risks or benefits associated with this combined treatment approach.

NCT00002001
Principal SponsorGlaxo Wellcome
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 13 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeHIV Infections

Criteria

4 inclusion criteria required to participate
Prophylaxis for PCP.
Patients with PCP may be randomized to study medication after contacting the sponsor and following a minimum 7-day course of therapy resulting in stabilization of their disease. Patients with stabilized disease must have fever < 39 C for at least 48 hours, p02 (on room air) >= 60 mm and an A/A gradient <= 30 mm.
HIV-1 seropositive by any federally licensed ELISA.
Willingness to give informed consent.
38 exclusion criteria prevent from participating
Ethionamide.
Probenecid.
Iodoquinol.
Metronidazole.
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 5 locations

Univ of Colorado Health Sciences Ctr

Denver, United StatesOpen Univ of Colorado Health Sciences Ctr in Google Maps

Georgetown Univ Med Ctr / Main Hosp 4

Washington D.C., United States

Vanderbilt School of Medicine

Nashville, United States

Saint Vincent's Hosp Med Centre

Darlinghurst, Australia
Completed5 Study Centers